NEWRON PHARMACEUT. EO-20 (NP5) — Tangible Net Worth Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets (€0.00) from net assets (€1.58 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore NP5 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
NEWRON PHARMACEUT. EO-20 Tangible Net Worth Ratio (2021–2024)
This chart shows how NEWRON PHARMACEUT. EO-20's Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of €1.58 Million with intangible assets of €0.00 EUR. For live market cap and overall valuation, see NEWRON PHARMACEUT. EO-20 market cap and net worth.
Annual Tangible Net Worth Ratio for NEWRON PHARMACEUT. EO-20 (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for NEWRON PHARMACEUT. EO-20 from 2021 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore NEWRON PHARMACEUT. EO-20 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | €1.46 Million | €0.00 | €63.91 Million | ▲ +0.0 pp |
| 2021 | 100.0% | €3.11 Million | €0.00 | €50.49 Million | — |